Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LONDON AND NEW YORK, JULY 28, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ: OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED THAT RAJ PATIL, PHD, CHIEF SCIENTIFIC OFFICER OF OKYO PHARMA HAS INCREASED HIS HOLDINGS WITH THE PURCHASE OF 3,363 OF THE COMPANY'S ORDINARY SHARES ON NASDAQ AT $1.49 PER SHARE, BRINGING HIS TOTAL HOLDING TO 20,030 ORDINARY SHARES. ABOUT OKYO PHARMA OKYO PHARMA LIMITED (NASDAQ: OKYO) IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, WITH ORDINARY SHARES LISTED FOR TRADING ON THE NASDAQ CAPITAL MARKET.

OKYO PHARMA ANNOUNCES PURCHASE OF SHARES BY CHIEF SCIENTIFIC OFFICER

LONDON AND NEW YORK, JULY 27, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED ITS PARTICIPATION IN THE BTIG BIOTECHNOLOGY CONFERENCE 2026 TAKING PLACE VIRTUALLY ON JULY 28-29, 2026.

OKYO PHARMA TO PARTICIPATE IN THE BTIG BIOTECHNOLOGY CONFERENCE 2026

LONDON AND NEW YORK, JULY 23, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED THAT OKYO PHARMA'S NON-EXECUTIVE DIRECTOR, JOHN BRANCACCIO HAS PURCHASED 5,000 OF THE COMPANY'S ORDINARY SHARES ON NASDAQ AT $1.48 PER SHARE, BRINGING HIS TOTAL HOLDING TO 35,201 SHARES.

OKYO PHARMA ANNOUNCES PURCHASE OF SHARES BY DIRECTOR

LONDON AND NEW YORK, JULY 23, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED THAT OKYO PHARMA'S CHIEF EXECUTIVE OFFICER, ROBERT J. DEMPSEY, HAS PURCHASED 15,000 OF THE COMPANY'S ORDINARY SHARES ON NASDAQ AT $1.54 PER SHARE.

OKYO PHARMA ANNOUNCES PURCHASE OF SHARES BY CHIEF EXECUTIVE OFFICER

LONDON AND NEW YORK, JULY 22, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED THAT ITS CHAIRMAN, MR. GABRIELE CERRONE, THROUGH PANETTA PARTNERS LTD, AN ENTITY IN WHICH HE HAS A BENEFICIAL INTEREST, HAS INCREASED HIS HOLDINGS WITH THE PURCHASE OF 22,500 ORDINARY SHARES AT $1.45 PER SHARE, BRINGING HIS TOTAL HOLDING TO 10,873,916 ORDINARY SHARES, WHICH IS 20.55% OF ISSUED SHARE CAPITAL.

OKYO PHARMA ANNOUNCES PURCHASE OF SHARES BY CHAIRMAN

LONDON AND NEW YORK, JULY 22, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED THAT GARY S. JACOB, PHD, CHIEF DEVELOPMENT OFFICER AND DIRECTOR OF OKYO PHARMA HAS INCREASED HIS HOLDINGS WITH THE PURCHASE OF 3,500 OF THE COMPANY'S ORDINARY SHARES ON NASDAQ AT $1.40 PER SHARE, BRINGING HIS TOTAL HOLDING TO 112,420 ORDINARY SHARES.

OKYO PHARMA ANNOUNCES PURCHASE OF SHARES BY CHIEF DEVELOPMENT OFFICER AND DIRECTOR

LONDON AND NEW YORK, JULY 22, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED THAT OKYO PHARMA'S CHIEF MEDICAL OFFICER, FLAVIO MANTELLI, MD, PHD, HAS PURCHASED 20,000 OF THE COMPANY'S ORDINARY SHARES ON NASDAQ AT $1.40 PER SHARE.

OKYO PHARMA ANNOUNCES PURCHASE OF SHARES BY CHIEF MEDICAL OFFICER

LONDON AND NEW YORK, JULY 21, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED A PRESENTATION AT THE H.C. WAINWRIGHT 6TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE BEING HELD ON WEDNESDAY, JULY 22, 2026.

OKYO PHARMA TO PRESENT AT THE H.C. WAINWRIGHT 6TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE

LONDON AND NEW YORK, JULY 21, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED THAT ITS CHAIRMAN, MR. GABRIELE CERRONE, THROUGH PANETTA PARTNERS LTD, AN ENTITY IN WHICH HE HAS A BENEFICIAL INTEREST, HAS INCREASED HIS HOLDINGS WITH THE PURCHASE OF 25,000 ORDINARY SHARES AT $1.40 PER SHARE, BRINGING HIS TOTAL HOLDING TO 10,851,416 ORDINARY SHARES, WHICH IS 20.51% OF ISSUED SHARE CAPITAL.

LONDON AND NEW YORK, JULY 20, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED THE FILING OF ITS ANNUAL REPORT ON FORM 20-F FOR THE FISCAL YEAR ENDED MARCH 31, 2026, WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (SEC). THE REPORT IS AVAILABLE ON THE SEC'S WEBSITE AND THE COMPANY'S INVESTOR RELATIONS PAGE. IN CONJUNCTION WITH THE FILING, THE COMPANY PROVIDED A POSITIVE CORPORATE UPDATE ON ITS FINANCIAL STRENGTH AND CLINICAL MOMENTUM.

OKYO PHARMA ANNOUNCES FILING OF ANNUAL REPORT WITH STRENGTHENED CASH POSITION AND ACCELERATED PHASE 3 PLANS

LONDON AND NEW YORK, JULY 08, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ:OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED POSITIVE FEEDBACK FROM ITS U.S. FOOD AND DRUG ADMINISTRATION (FDA) TYPE D MEETING, VALIDATING THE COMPANY'S REGULATORY AND CLINICAL PATH FORWARD FOR URCOSIMOD AND SUPPORTING ADVANCEMENT INTO A GLOBAL PHASE 3 PIVOTAL TRIAL FOR NCP.

OKYO PHARMA REPORTS POSITIVE FEEDBACK FROM FDA TYPE D MEETING AND ACCELERATES URCOSIMOD INTO GLOBAL PHASE 3 PIVOTAL TRIAL FOR NEUROPATHIC CORNEAL PAIN

LONDON AND NEW YORK, JULY 07, 2026 (GLOBE NEWSWIRE) -- OKYO PHARMA LIMITED (NASDAQ: OKYO), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF NEUROPATHIC CORNEAL PAIN (NCP) AND ANTERIOR SEGMENT EYE DISEASES, TODAY ANNOUNCED PARTICIPATION AT THE PIPER SANDLER VIRTUAL OPHTHALMOLOGY SYMPOSIUM BEING HELD ON THURSDAY, JULY 9, 2026. DETAILS OF THE EVENT ARE AS FOLLOWS: PRESENTERS: ROBERT J.

OKYO Pharma Limited

OKYO

Price

Financial Reports

No items found.

Press Releases

OKYO Pharma Limited

OKYO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

OKYO